Iovance Biotherapeutics

Yahoo Finance • 9 days ago

Neurocrine Biosciences Details $2.9B Soleno Buyout, Touts Vykat XR as Potential Blockbuster

Neurocrine Biosciences logo 3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking Neurocrine Biosciences (NASDAQ:NBIX) detailed its planned acquisition of Soleno Therapeutics on a conference call Monday, outlining the deal terms, the s... Full story

Yahoo Finance • last month

Tempus AI, Inc. (TEM) Announces Strategic Deal with Merck to Fast-Track AI-Driven Precision Medicine

Tempus AI, Inc. (NASDAQ:TEM) is among the ARK Invest Stock Portfolio: Top 10 Stock Picks for 2026. On March 3, the company announced a strategic partnership with Merck to fast-track the development of AI-driven precision medicine and suppo... Full story

Yahoo Finance • last month

UBS Raises PT on Iovance Biotherapeutics (IOVA)

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the Low Risk Penny Stocks to Buy Now. On March 5, UBS analyst David Dai raised the firm’s price target on Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) from $2 to $4, while maintaining a... Full story

Yahoo Finance • 2 months ago

Iovance Biotherapeutics GAAP EPS of -$0.18 in-line, revenue of $86.71M beats by $5.7M

* Iovance Biotherapeutics press release [https://seekingalpha.com/pr/20410351-iovance-biotherapeutics-highlights-strong-fourth-quarter-and-full-year-2025-results-business] (IOVA [https://seekingalpha.com/symbol/IOVA]): Q4 GAAP EPS of -$0... Full story

Yahoo Finance • 2 months ago

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltratin... Full story

Yahoo Finance • 2 months ago

Is Iovance Biotherapeutics Inc. (IOVA) One of the Best Immunotherapy Stocks to Buy According to Hedge Funds?

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is one of the best immunotherapy stocks to buy according to hedge funds. On February 5, Goldman Sachs lifted the price target on Iovance Biotherapeutics Inc. (NASDAQ:IOVA) to $2 from $1.50 while m... Full story

Yahoo Finance • 2 months ago

Iovance Biotherapeutics (IOVA) Gives Update on Revenue Guidance, Lung Cancer Cure

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is one of the best stocks under $3 to invest in. On January 9, Iovance Biotherapeutics Inc. (NASDAQ:IOVA) announced that it expects to achieve its previously disclosed full-year 2025 revenue guida... Full story

Yahoo Finance • 2 months ago

Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma

SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL)... Full story

Yahoo Finance • 3 months ago

Barclays Adjusts Valuation Targets for Iovance Biotherapeutics (IOVA) Amid Biotech Sector Review

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is one of the best biotech penny stocks to buy according to analysts. On December 17, Barclays analyst Etzer Darout raised the firm’s price target on Iovance Biotherapeutics to $10 from $9, while... Full story

Yahoo Finance • 4 months ago

2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street

Key Points A clinical hold and a complex commercial path make Intellia Therapeutics' outlook uncertain. Despite steadily growing revenue, Iovance Biotherapeutics faces nearly insurmountable challenges. 10 stocks we like better than Intell... Full story

Yahoo Finance • 5 months ago

Iovance Biotherapeutics reports mixed Q3 results; reaffirms FY25 outlook

* Iovance Biotherapeutics press release [https://seekingalpha.com/pr/20296680-iovance-biotherapeutics-highlights-business-achievements-pipeline-milestones-and-third] (IOVA [https://seekingalpha.com/symbol/IOVA]): Q3 GAAP EPS of -$0.25 be... Full story

Yahoo Finance • 6 months ago

IOVANCE INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Continues Investigation on Behalf of Long-Term Iovance, Inc. Stockholders

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Iovance (IOVA) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in Iovance between May 9, 2024 an... Full story

Yahoo Finance • 6 months ago

Is Iovance Biotherapeutics Stock Your Ticket to Becoming a Millionaire?

Key Points Iovance Biotherapeutics was the first drug developer to win FDA approval of an immune cell/T-cell therapy. The underlying science, however, may offer more long-term potential than the single drug in question. This stock’s treme... Full story

Yahoo Finance • 6 months ago

IOVANCE (IOVA) ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Iovance Biotherapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Iovance (IOVA) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in Iovance between May 9, 2024 an... Full story

Yahoo Finance • 7 months ago

Shares of WOR Now Oversold

In trading on Wednesday, shares of Worthington Enterprises Inc (Symbol: WOR) entered into oversold territory, changing hands as low as $50.55 per share. We define oversold territory using the Relative Strength Index, or RSI, which is a te... Full story

Yahoo Finance • 7 months ago

Can This Beaten-Down Stock Bounce Back?

Key Points Iovance Biotherapeutics' cancer therapy, Amtagvi, is experiencing decent sales growth. However, the biotech faces some challenges that will make it difficult to turn a profit. Though there could be some catalysts on the way, Io... Full story

Yahoo Finance • 7 months ago

Advancing Cancer Research Brings New Hope for Patients Worldwide

NetworkNewsWire Editorial Coverage NEW YORK, Sept. 17, 2025 /PRNewswire/ -- Progress in RNA-based medicines, immunotherapies and targeted treatments is not simply desirable, it is a critical necessity. Deadly cancers such as glioblastoma... Full story

Yahoo Finance • 8 months ago

Iovance Biotherapeutics to Present at Upcoming Conferences

SAN CARLOS, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies... Full story

Yahoo Finance • 8 months ago

Biggest stock movers Tuesday: PANW, BLNK, and more

[financial graph on technology abstract background] monsitj Stock futures edged lower in Tuesday’s premarket trading after a subdued start to a pivotal week marked by key Federal Reserve speeches, major retail earnings, and investor cauti... Full story

Yahoo Finance • 8 months ago

Iovance gets conditional Health Canada approval for Amtagvi

[Cancer Outbreak] wildpixel/iStock via Getty Images Iovance Biotherapeutics (NASDAQ:IOVA [https://seekingalpha.com/symbol/IOVA]) shares rose post market after it received Health Canada approval with conditions for its T-cell immunotherapy... Full story